Review




Structured Review

Santa Cruz Biotechnology rab9
Rab9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/Rab+9+siRNA/pm41274424-80-8-12
Average 93 stars, based on 6 article reviews
rab9 - by Bioz Stars, 2026-10
93/100 stars

Images

Related Articles

Blocking Assay:

Article Title: Decreased SREBP2 of the striatal cell relates to disrupted protein degradation in Huntington's disease.
Article Snippet: This study delineated the intricate relation between cholesterol metabolism, protein degradation mechanisms, and the pathogenesis of Huntington’s disease (HD).. Through investigations using both animal models and cellular systems, we have observed significant alterations in cholesterol levels, particularly in the striatum, which is the primary lesion site in HD.. Our findings indicate the dysregulation of cholesterol metabolism-related factors, such as LDLR and SREBP2, in HD, which may contribute to disease progression.

Knockdown:

Article Title: Disruption of Rab9-dependent mitophagy contributes to menopause-induced sarcopenia.
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc- 44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528) and siRNA transfection medium (sc-36868), according to the manufacturer’s instruction. ..

Article Title: Association of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 With Angiotensin II Type 1 Receptor Impacts Mitochondrial Quality Control, Offering Promise for the Treatment of Vascular Senescence
Article Snippet: .. For ERK1, ERK2, and Rab9 RNA knockdown, cells were transfected with ERK1, ERK2, Rab9, or control siRNA (Santa Cruz, Cat #sc-29307, sc-35335, sc-44065, sc-37007) using the siRNA transfection reagent (Santa Cruz, Cat #sc-29528), according to the manufacturer's protocol. .. For siRNA targeting Atg7 , we transfected cells with Atg7 or control (Thermo Fisher Scientific, Cat #s20650, #4390843) using the Lipofectamine RNAiMAX transfection reagent (InvitrogenTM, 13778150), according to the manufacturer's protocol.

Article Title: Estrogen Plays a Crucial Role in Rab9‐Dependent Mitochondrial Autophagy, Delaying Arterial Senescence
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528), according to the manufacturer’s instruction. .. For ATG7 RNA knockdown, cells were transfected with the reagent (13778150; Invitrogen), according to the manufacturer’s protocol.

Transfection:

Article Title: Disruption of Rab9-dependent mitophagy contributes to menopause-induced sarcopenia.
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc- 44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528) and siRNA transfection medium (sc-36868), according to the manufacturer’s instruction. ..

Article Title: Association of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 With Angiotensin II Type 1 Receptor Impacts Mitochondrial Quality Control, Offering Promise for the Treatment of Vascular Senescence
Article Snippet: .. For ERK1, ERK2, and Rab9 RNA knockdown, cells were transfected with ERK1, ERK2, Rab9, or control siRNA (Santa Cruz, Cat #sc-29307, sc-35335, sc-44065, sc-37007) using the siRNA transfection reagent (Santa Cruz, Cat #sc-29528), according to the manufacturer's protocol. .. For siRNA targeting Atg7 , we transfected cells with Atg7 or control (Thermo Fisher Scientific, Cat #s20650, #4390843) using the Lipofectamine RNAiMAX transfection reagent (InvitrogenTM, 13778150), according to the manufacturer's protocol.

Article Title: Estrogen Plays a Crucial Role in Rab9‐Dependent Mitochondrial Autophagy, Delaying Arterial Senescence
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528), according to the manufacturer’s instruction. .. For ATG7 RNA knockdown, cells were transfected with the reagent (13778150; Invitrogen), according to the manufacturer’s protocol.

Control:

Article Title: Disruption of Rab9-dependent mitophagy contributes to menopause-induced sarcopenia.
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc- 44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528) and siRNA transfection medium (sc-36868), according to the manufacturer’s instruction. ..

Article Title: Association of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 With Angiotensin II Type 1 Receptor Impacts Mitochondrial Quality Control, Offering Promise for the Treatment of Vascular Senescence
Article Snippet: .. For ERK1, ERK2, and Rab9 RNA knockdown, cells were transfected with ERK1, ERK2, Rab9, or control siRNA (Santa Cruz, Cat #sc-29307, sc-35335, sc-44065, sc-37007) using the siRNA transfection reagent (Santa Cruz, Cat #sc-29528), according to the manufacturer's protocol. .. For siRNA targeting Atg7 , we transfected cells with Atg7 or control (Thermo Fisher Scientific, Cat #s20650, #4390843) using the Lipofectamine RNAiMAX transfection reagent (InvitrogenTM, 13778150), according to the manufacturer's protocol.

Article Title: Estrogen Plays a Crucial Role in Rab9‐Dependent Mitochondrial Autophagy, Delaying Arterial Senescence
Article Snippet: .. For Rab9 RNA knockdown, cells were transfected with Rab9 or control siRNA (Santa Cruz, sc44065, sc-37007) using the siRNA Transfection Reagent (Santa Cruz, sc-29528), according to the manufacturer’s instruction. .. For ATG7 RNA knockdown, cells were transfected with the reagent (13778150; Invitrogen), according to the manufacturer’s protocol.

Polyacrylamide Gel Electrophoresis:

Article Title: Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson’s Disease Patients
Article Snippet: Immortalized fibroblasts were lysed in RIPA buffer with 1× complete protease inhibitor (Roche, Mannheim, Germany). .. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis was performed using antibodies against Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1), Tom20 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-17764), Rab9 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-74482), and β-Actin (Thermo Scientific, Braunschweig, Germany, MA1-744). ..

Article Title: Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson's Disease Patients.
Article Snippet: Immortalized fibroblasts were lysed in RIPA buffer with 1× complete protease inhibitor (Roche, Mannheim, Germany). .. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis was performed using antibodies against Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1), Tom20 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-17764), Rab9 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-74482), and β-Actin (Thermo Scientific, Braunschweig, Germany, MA1-744). ..

Western Blot:

Article Title: Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson’s Disease Patients
Article Snippet: Immortalized fibroblasts were lysed in RIPA buffer with 1× complete protease inhibitor (Roche, Mannheim, Germany). .. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis was performed using antibodies against Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1), Tom20 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-17764), Rab9 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-74482), and β-Actin (Thermo Scientific, Braunschweig, Germany, MA1-744). ..

Article Title: Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson's Disease Patients.
Article Snippet: Immortalized fibroblasts were lysed in RIPA buffer with 1× complete protease inhibitor (Roche, Mannheim, Germany). .. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis was performed using antibodies against Miro1 (Sigma Aldrich, Munich, Germany, WH0055288M1), Tom20 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-17764), Rab9 (Santa Cruz Biotechnologies, Dallas, TX, USA, sc-74482), and β-Actin (Thermo Scientific, Braunschweig, Germany, MA1-744). ..

Article Title: Mutations in RHOT1 Disrupt Endoplasmic Reticulum–Mitochondria Contact Sites Interfering with Calcium Homeostasis and Mitochondrial Dynamics in Parkinson's Disease
Article Snippet: Fibroblasts were lysed in RIPA buffer containing 1 × complete protease inhibitor (Roche). .. Western blot analysis was performed with antibodies against Miro1 (WH0055288M1; Sigma–Aldrich, Munich, Germany), LC3-I/II (2775; Cell Signaling), Hsp60 (4870; Cell Signaling), Tom20 (sc-17764; Santa Cruz Biotechnologies), Rab9 (sc-74482; Santa Cruz Biotechnologies), MnSOD (ab13533; Abcam), anti-V5 (R960-25; Novex, R96125; Sigma–Aldrich), and β-actin (MA1-744; Thermo Scientific). ..



Similar Products

90
Thermo Fisher mouse anti-rab9
Mouse Anti Rab9, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/mouse+anti+rab9/pm40562935-1048-39-13
Average 90 stars, based on 1 article reviews
mouse anti-rab9 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology rab9
Rab9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/Rab+9+siRNA/pm41274424-80-8-12
Average 93 stars, based on 1 article reviews
rab9 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc rab9
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Rab9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/Rab9+Rabbit+mAb/bio_rxiv__2025__10__31__685804-217-126-130
Average 92 stars, based on 1 article reviews
rab9 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc rabbit monoclonal anti rab9 d22a6
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Rabbit Monoclonal Anti Rab9 D22a6, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/Rab9+Rabbit+mAb/pmc12588189-18-0-5
Average 92 stars, based on 1 article reviews
rabbit monoclonal anti rab9 d22a6 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

90
Pfleger GmbH venus-rab9
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Venus Rab9, supplied by Pfleger GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/venus+rab9/pmc12159506-82-0-3
Average 90 stars, based on 1 article reviews
venus-rab9 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

93
Addgene inc pegfp c3 rab9
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Pegfp C3 Rab9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/mCherry-Rab11a-7+(Plasmid+%2355124)/pm40174331-61-46-59
Average 93 stars, based on 1 article reviews
pegfp c3 rab9 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
ABclonal Biotechnology anti rab9
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Anti Rab9, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/RAB9A+Rabbit+pAb/pm40197538-267-39-41
Average 93 stars, based on 1 article reviews
anti rab9 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Addgene inc gfprab9 wt
(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or <t>RAB9</t> KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.
Gfprab9 Wt, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rab9/GFP-rab9+WT+(Plasmid+%2312663)/10__1016_slash_j__bbrc__2025__151800-62-29-34
Average 93 stars, based on 1 article reviews
gfprab9 wt - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


(a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or RAB9 KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.

Journal: bioRxiv

Article Title: ER-to-Golgi Trafficking is a Nutrient-Sensitive Checkpoint Linking Glucose Starvation to Cell Surface Remodeling

doi: 10.1101/2025.10.31.685804

Figure Lengend Snippet: (a–f) U2OS cells (wild-type [WT], ULK1/2 double knockout [DKO], ATG7 knockout [KO], or RAB9 KO were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in Dulbecco’s Modified Eagle Medium (DMEM) with or without glucose for 1 h, followed by biotin treatment for 30 min. ( a ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( b ) Percentage of cells (mean ± S.E.M., n = 3 biological replicates, >37 cells per replicate) with Golgi-localized E-cadherin. ( c–f ) Representative immunoblot analyses show protein levels of ULK1, ULK2, ATG7, or RAB9 in WT and indicated KO cell lines; * indicates nonspecific band in ( e ). ( g–i ) Rescue of glucose starvation–induced ER-to-Golgi trafficking inhibition was evaluated in U2OS ULK1/2 DKO cells stably expressing empty vector (EV), WT ULK1, kinase-dead ULK1 (K46A), or AMPK-resistant ULK1 (4SA). Cells were transfected with the E-cadherin RUSH construct, incubated in DMEM with or without glucose for 1 h, and treated with biotin for 30 min. ( g ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( h ) Golgi-localized E-cadherin in U2OS ULK1/2 DKO cells expressing WT or mutant forms of ULK (mean ± S.E.M., n = 3 biological replicates, >30 cells per replicate). ( i ) Representative immunoblot analysis shows AMPK activity as indicated by total and phospho-ACC, and ULK1 expression, and AMPK-mediated phosphorylation of ULK1 at S555 in the indicated cell lines. ( j–l ) WT U2OS cells were transfected with the E-cadherin RUSH construct. After 48 h, cells were pre-treated with compound C (5 μM, 4 h) or MRT68921 (1 μM, 24 h) and incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( j ) Representative immunofluorescence images following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( k ) Golgi-localized E-cadherin in U2OS cells before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >103 cells per replicate). ( l ) Representative immunoblot analysis demonstrates activity of each inhibitor post biotin treatment. ( m–o ) WT or Prkaa1/2 (AMPKα1/2) DKO murine embryonic fibroblasts (MEFs) were transfected with the E-cadherin RUSH construct. After 48 h, cells were incubated in DMEM with or without glucose for 1 h, followed by biotin treatment for 30 min. ( m ) Representative immunofluorescence images captured following anti-GM130 and DAPI staining show changes in reporter distribution after biotin addition and/or glucose starvation. ( n ) Golgi-localized E-cadherin in in WT and AMPK α1/2 DKO MEFs before and after glucose starvation (mean ± S.E.M., n = 3 biological replicates, >33 cells per replicate). ( o ) Levels of phosphorylated ACC and ULK1 in WT and AMPK α1/2 DKO MEFs after 1-h glucose starvation. Statistical significance was analyzed with one-way ANOVA followed by Tukey’s multiple comparisons. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant. Scale bar, 10 μm.

Article Snippet: After blocking the membrane with 5% skim milk, blots were probed with antibodies directed against the following targets: ULK1 (Cat. No. 8058, Cell Signaling), p-ULK1 (S555) (Cat. No. 5869, Cell Signaling), ATG7 (Cat. No. 2631, Cell Signaling), ULK2 (Cat. No. HPA009027, Sigma-Aldrich), ATG13 (Cat. No. SAB4200100, Millipore Sigma), p-ATG13 (S318) (Cat. No. 600-401-C49 Rockland), GFP (Cat. No. ab6556, Abcam), FLAG (Cat. No. F1804, Millipore Sigma), HA (Cat. No. 3724, Cell Signaling), GAPDH (Cat. No. G9545, Sigma Aldrich), p-ACC (S79) (Cat. No. 11818, Cell Signaling), ACC (Cat. No. 3676, Cell Signaling), p-S6 (S235/236) (Cat. No. 4858, Cell Signaling), S6 (Cat. No. 2317, Cell Signaling), SEC24C (Cat. No. 8531, Cell Signaling), SEC24A (Cat. No. 15958-1-AP, Proteintech), SEC24B (Cat. No. A304-876A, Bethyl), SEC24D (Cat. No. 14687, Cell Signaling), and RAB9 (Cat. No. 5133, Cell Signaling).

Techniques: Double Knockout, Knock-Out, Transfection, Construct, Incubation, Modification, Immunofluorescence, Staining, Western Blot, Inhibition, Stable Transfection, Expressing, Plasmid Preparation, Mutagenesis, Activity Assay, Phospho-proteomics